Richard Gregory
Direktor/Vorstandsmitglied bei CANBRIDGE PHARMACEUTICALS INC.
Aktive Positionen von Richard Gregory
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CANBRIDGE PHARMACEUTICALS INC. | Direktor/Vorstandsmitglied | 21.04.2020 | - |
Independent Dir/Board Member | 21.04.2020 | - |
Karriereverlauf von Richard Gregory
Ehemalige bekannte Positionen von Richard Gregory
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
PROMIS NEUROSCIENCES, INC. | Direktor/Vorstandsmitglied | 18.10.2016 | 27.04.2023 |
Independent Dir/Board Member | 18.10.2016 | 27.04.2023 | |
IMMUNOGEN, INC. | Technik-/Wissenschafts-/F&E-Leiter | 05.01.2015 | 30.08.2019 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2003 | 01.01.2014 |
Canbridge Pharmaceuticals, Inc. (United States)
Canbridge Pharmaceuticals, Inc. (United States) BiotechnologyHealth Technology Part of CANbridge Pharmaceuticals Inc., Canbridge Pharmaceuticals is a rare disease-focused biopharmaceutical company based in Cambridge, MA. Canbridge Pharmaceuticals, Inc. (United States) was established in 2012 and is committed to researching, developing, and commercializing transformative therapies for rare diseases. | Direktor/Vorstandsmitglied | 28.04.2020 | - |
Technik-/Wissenschafts-/F&E-Leiter | 28.04.2020 | - | |
Q32 BIO INC. | Direktor/Vorstandsmitglied | 01.01.2015 | - |
Independent Dir/Board Member | 01.01.2015 | - |
Ausbildung von Richard Gregory
University of Massachusetts | Doctorate Degree |
Virginia Polytechnic Institute & State University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Kanada | 2 |
Cayman Islands | 2 |
Operativ
Director/Board Member | 4 |
Chief Tech/Sci/R&D Officer | 3 |
Independent Dir/Board Member | 3 |
Sektoral
Health Technology | 7 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
PROMIS NEUROSCIENCES, INC. | Health Technology |
CANBRIDGE PHARMACEUTICALS INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
ImmunoGen, Inc.
ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Homology Medicines, Inc.
Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA. | Health Technology |
Canbridge Pharmaceuticals, Inc. (United States)
Canbridge Pharmaceuticals, Inc. (United States) BiotechnologyHealth Technology Part of CANbridge Pharmaceuticals Inc., Canbridge Pharmaceuticals is a rare disease-focused biopharmaceutical company based in Cambridge, MA. Canbridge Pharmaceuticals, Inc. (United States) was established in 2012 and is committed to researching, developing, and commercializing transformative therapies for rare diseases. | Health Technology |
- Börse
- Insiders
- Richard Gregory
- Erfahrung